SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is experiencing an explosive surge, driven by its new partnership with crypto.com/us to launch an event-based prediction markets product in the USA. The community is buzzing, with many anticipating further significant gains and a short squeeze due to its notably low float, while others express caution about potential offerings and an eventual correction after such a rapid ascent.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is currently a hot topic, driven by a notable surge in trading volume and price, and intense community speculation regarding an imminent catalyst. Investors are keenly watching significant call option activity and discussing potential institutional accumulation, believing POET's Optical Interposer technology is a transformative solution for efficient AI data center interconnects. This has cemented the company's position at the heart of conversations within the rapidly expanding photonics sector.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial (RILY) is trending as the company just filed its outstanding Form 10-Qs, achieving NASDAQ compliance and reporting strong third-quarter financial results. This development has ignited widespread community discussion about a potential short or gamma squeeze, given the stock's high short interest and low float, with many anticipating a significant price recovery.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a central topic amidst the J.P. Morgan Healthcare Conference, fueled by recent positive Phase 2 data for its obesity drug VK2735 and comments from a peer CEO regarding substantial M&A opportunities in the weight-loss sector. The community is actively debating the potential for a major partnership or acquisition, with discussions also focusing on the expected timeline for FDA clarity on VK2735's direct progression to Phase 3, contrasting its "best-in-class" prospects against competitors, and observations on short-term price volatility.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is trending due to recent announcements surrounding a presidential executive order on critical minerals and ongoing high-level discussions involving US, Denmark, and Greenland officials regarding strategic rare earth resources. The community is highly engaged, anticipating potential US government investment in CRML's Greenland-based Tanbreez project and significant short squeeze potential.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid a significant computing partnership for AI infrastructure and recent regulatory attention on data center electricity costs, sparking debate on its substantial AI investments. The community is divided, with some highlighting long-term AI leadership and a recent bullish analyst upgrade as buying signals, while others express concerns over the profitability of AI scaling and market underperformance.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending due to a surge in bullish sentiment, fueled by rising lithium prices and the company's active battery recycling operations, including the Moss Landing contract. Community discussions highlight ABAT's long-term potential within the "Made in USA" critical minerals sector, especially with recent updates indicating zero dilution, suggesting a strategic path forward for the company.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is trending due to significant progress in U.S. deep-sea mining regulations, with the White House and OIRA concluding review and approving NOAA's revised policy for consolidating exploration and recovery permits, a move that could drastically cut project timelines. This regulatory clarity is fueling strong bullish sentiment and driving discussions around TMC's potential to secure U.S. critical mineral independence and break key resistance levels, as the community eagerly anticipates future permit milestones.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending following a widespread and prolonged service outage that has left many customers across the nation without wireless and data services, sparking significant frustration and online discussion. While users express anger over the disruption and question network reliability, some contrarian voices view this as a potential buying opportunity. The incident intensifies scrutiny on telecommunication network resilience within the competitive sector, with speculation even touching on potential cyberattacks.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is a key focus, with strong anticipation for its upcoming earnings report expected to influence the broader semiconductor sector amid robust AI chip demand. The community is actively discussing TSM's expanding advanced packaging capacity and a potential US-Taiwan trade deal involving new US facilities, while also monitoring geopolitical tensions. This confluence of factors is driving significant options activity and varied perspectives on its recent all-time highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO...

Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Trading Down 23.9% - Here's What Happened...

<ul class="summary-bullets"><li>Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency.</li><li>The company added that it no longer expects to initiate the trial in question in the first half of 2026.&nbsp;</li><li>Cassava discontinued Simufilam’s study in mild-to-moderate Alzheimer’s disease in March.</li></ul> Shares of Cassava Sciences, Inc.’s slid a deep 24% on Friday after the U.S. Food and Drug Administration placed a full clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy.The stock is now on track for its worst day in about 9 months.The company was informed by the FDA of the hold in a letter earlier this week, it said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069530/000143774925038313/sava20251218_8k.htm">filing</a> with the Securities and Exchanges Commission. The company now has to provide the agency with additional information, including additional pre-clinical data, and modify the protocol design.Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the first half of 2026.The company failed to provide a new timing for the study, and said it would depend on its ability to provide the requested information and on satisfactory completion of FDA’s review.<h2 class="st-heading-2">Cassava Hits Multiple Roadblocks With Simufilam</h2>Cassava <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-drops-over-30-percent-after-drug-fails-study/ch7yzVjRbdz">discontinued</a> Simufilam’s study in mild-to-moderate Alzheimer’s disease in March after the drug did not fare better than placebo in reducing cognitive or functional decline in a late-stage study. The company discontinued its efforts to develop the drug for Alzheimer’s disease and phased out the program and then committed to evaluating the drug’s potential in TSC-related epilepsy.Tuberous Sclerosis Complex (TSC) is a rare genetic disorder causing non-cancerous tumors (hamartomas) to grow in many organs, primarily the brain, skin, kidneys, heart, lungs, and eyes. It can lead to symptoms including seizures, developmental delays, intellectual disabilities, and skin abnormalities.According to Austin-based Cassava, TSC affects nearly 50,000 people in the US and epilepsy is one of the most common neurological features of TSC, occurring in 84% of patients. Current therapies for the condition include antiepileptic drugs and mTOR inhibitors which are not fully effective, and are associated with serious adverse events, the company said in November.Cassava decided to study Simufilam in TSC-related epilepsy on the results of two sophisticated studies conducted in animals that support the drug’s potential, CEO Rick Barry said last month. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA fell from ‘bearish’ to ‘extremely bearish' territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user highlighted a buying opportunity.<stembedurl>https://www.stocktwits.com/MrStockxy/message/639701864</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 8% this year and by 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-heads-for-its-best-day-in-over-8-months-rally-isn-t-only-about-trump/cLe0GDaREst">Rocket Lab Stock Heads For Its Best Day In Over 8 Months — And The Rally Isn’t Only About Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?

FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.

Equity

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Cassava Sciences confirms an FDA clinical hold on its simufilam epilepsy trial, delaying plans and requiring more data despite strong cash reserves.read more...

Cassava Sciences (NASDAQ:SAVA) CEO Purchases $201,808.75 in Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The stock was bought...

Cassava Sciences Sees Unusually High Options Volume (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 8,896 call options on the company. This represents an...

Insider Buying: Cassava Sciences (NASDAQ:SAVA) CEO Acquires 73,385 Shares of Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction on Wednesday, November 19th. The stock was bought at an average...

Cassava Sciences (NASDAQ:SAVA) Trading Down 3% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Shares Down 3% - Time to Sell...

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders. If you...

Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported that its oral drug Simufilam did not yield positive results in patients with mild to moderate Alzheimer’s disease in its second Phase 3 study.The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said.Cassava added that it would discontinue the Alzheimer’s disease development program with Simufilam by the end of the second quarter of 2025. &nbsp;REFOCUS-ALZ was discontinued on Nov. 25 last year after the company identified that a previous phase 3 study failed to yield positive results.Cassava CEO Rick Barry acknowledged the results were "unambiguous" and added that the company was “disappointed.”“Cassava will discontinue all efforts to develop Simufilam for Alzheimer’s disease, and we expect to phase out the program by the end of Q2 2025,” he said.The CEO added that the company has initiated preclinical studies to gauge the potential of Simufilam in treating TSC-related epilepsy.Company CFO Eric Schoen said the firm continues to be committed to enhancing shareholder value. “Cassava is well-capitalized with approximately $128.6 million in cash and cash equivalents as of Dec. 31, 2024,” he added.Cassava reported a net loss of $27.60 million in the three months ended December 2024 compared to a net loss of $20.92 million in the corresponding quarter of 2023.On Stocktwits, retail sentiment about Cassava Sciences climbed further into the ‘bullish’ territory (60/100), while message volume jumped from ‘normal’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:650/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_25_at_1_50_58_PM_png_d88af5aac9.webp" alt="SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits" width="650" height="146"><figcaption>SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expects the share price to drop further in the coming days.<stembedurl>https://stocktwits.com/pg3015/message/609181500</stembedurl>Another user expressed optimism, highlighting the company’s debt-free status.<stembedurl>https://stocktwits.com/mcrotary/message/609180826</stembedurl>SAVA stock has lost over 30% this year and is down by over 90% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/merck-enters-license-agreement-with-china-based-hengrui-pharma/ch7yxJsRbdw">Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful

The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025. 

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SAVA News

SAVACassava Sciences Inc